Form 4: Catalyst Pharmaceuticals Executive Sells Shares After Option Exercise

A Catalyst Pharmaceuticals executive, Gary Ingenito, exercised stock options and sold a portion of the acquired shares on the open market.

Summary

• Gary Ingenito, Chief Medical and Regulatory Officer at Catalyst Pharmaceuticals, exercised options to purchase 12,000 shares of common stock at a price of $4.01 per share on November 27, 2024.
• Following the option exercise, Mr. Ingenito sold 8,631 shares at $22.74 per share and 3,369 shares at $22.673 per share on the open market.
• After these transactions, Mr. Ingenito directly owns 51,391 shares of common stock and 1,041,631 options to purchase common stock.
• The sales were for personal reasons and not due to any disagreement with the company.

Sentiment

Score: 5

Explanation: The document is a routine filing of stock transactions by an executive, which is neither positive nor negative for the company's overall outlook.

Management Comments

• The shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.

Industry Context

This is a routine Form 4 filing, which is common for executives who exercise stock options and sell shares. It is a normal part of executive compensation and portfolio management.

Comparison to Industry Standards

• Executive stock option exercises and subsequent sales are common across the pharmaceutical industry.
• The reported transactions are within the typical range for executives at similar companies.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine executive stock sales.

Key Dates

Keywords

Catalyst Pharmaceuticals, stock options, insider trading, share sale, executive, CPRX, Gary Ingenito